Dual Interleukin-4/Interleukin-13 Blocker-induced Arthralgia Treated Successfully with Upadacitinib in a Patient with Atopic Dermatitis.
作者信息
Tanji Takayuki, Watabe Daisuke, Arakawa Nobuyuki, Kamada Hirofumi, Amano Hiroo
机构信息
Department of Dermatology, Iwate Medical University School of Medicine, 2-1-1, Idaidori, Yahaba-cho, Shiwa-gun, Iwate 028-3695, Japan.
出版信息
Acta Derm Venereol. 2023 Apr 27;103:adv5326. doi: 10.2340/actadv.v103.5326.
Abstract
摘要
相似文献
1
Dual Interleukin-4/Interleukin-13 Blocker-induced Arthralgia Treated Successfully with Upadacitinib in a Patient with Atopic Dermatitis.
Acta Derm Venereol. 2023 Apr 27;103:adv5326. doi: 10.2340/actadv.v103.5326.
2
Treatment of Severe Atopic Dermatitis With Upadacitinib in Clinical Practice: Short-Term Efficacy and Safety Results.
J Investig Allergol Clin Immunol. 2023 Jun 15;33(3):211-213. doi: 10.18176/jiaci.0831. Epub 2022 Jun 7.
3
Upadacitinib improved alopecia areata in a patient with atopic dermatitis: A case report.
Dermatol Ther. 2022 Apr;35(4):e15346. doi: 10.1111/dth.15346. Epub 2022 Feb 10.
4
Improvement of dupilumab-associated conjunctivitis after switching to upadacitinib in a patient with atopic dermatitis.
Dermatol Ther. 2022 Jul;35(7):e15575. doi: 10.1111/dth.15575. Epub 2022 May 20.
5
Atopic Dermatitis and Ulcerative Colitis Successfully Treated with Upadacitinib.
Medicina (Kaunas). 2023 Mar 10;59(3):542. doi: 10.3390/medicina59030542.
6
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2021 Jun 5;397(10290):2169-2181. doi: 10.1016/S0140-6736(21)00589-4. Epub 2021 May 21.
7
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
Lancet. 2021 Jun 5;397(10290):2151-2168. doi: 10.1016/S0140-6736(21)00588-2. Epub 2021 May 21.
8
Concurrent chronic alopecia areata and severe atopic dermatitis successfully treated with upadacitinib.
Int J Dermatol. 2022 Nov;61(11):e416-e417. doi: 10.1111/ijd.16316. Epub 2022 Jun 20.
9
Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results.
J Allergy Clin Immunol. 2022 Mar;149(3):977-987.e14. doi: 10.1016/j.jaci.2021.07.036. Epub 2021 Aug 14.
10
Concurrent vitiligo and atopic dermatitis successfully treated with upadacitinib: a case report.
J Dermatolog Treat. 2023 Dec;34(1):2200873. doi: 10.1080/09546634.2023.2200873.
本文引用的文献
1
Significance of Interleukin (IL)-4 and IL-13 in Inflammatory Arthritis.
Cells. 2021 Nov 3;10(11):3000. doi: 10.3390/cells10113000.
2
Development of arthralgia during treatment with dupilumab in a patient with atopic dermatitis.
J Dermatol. 2021 Aug;48(8):e397-e398. doi: 10.1111/1346-8138.15965. Epub 2021 May 14.
3
Polyenthesitis during treatment with dupilumab for atopic dermatitis.
J Eur Acad Dermatol Venereol. 2020 Jul;34(7):e319-e321. doi: 10.1111/jdv.16239. Epub 2020 Feb 19.
4
Acute arthritis and arthralgia as an adverse drug reaction to dupilumab.
Clin Exp Dermatol. 2020 Mar;45(2):262-263. doi: 10.1111/ced.14050. Epub 2019 Sep 6.
5
Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2).
J Dermatol Sci. 2019 May;94(2):266-275. doi: 10.1016/j.jdermsci.2019.02.002. Epub 2019 Mar 12.
6
Development of inflammatory arthritis and enthesitis in patients on dupilumab: a case series.
Br J Dermatol. 2019 Nov;181(5):1068-1070. doi: 10.1111/bjd.18031. Epub 2019 Jul 18.
7
Emerging therapies for atopic dermatitis: JAK inhibitors.
J Am Acad Dermatol. 2018 Mar;78(3 Suppl 1):S53-S62. doi: 10.1016/j.jaad.2017.12.019. Epub 2017 Dec 15.
8
JAK inhibitors in dermatology: The promise of a new drug class.
J Am Acad Dermatol. 2017 Apr;76(4):736-744. doi: 10.1016/j.jaad.2016.12.005. Epub 2017 Jan 28.
9
Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches.
J Allergy Clin Immunol. 2014 Oct;134(4):769-79. doi: 10.1016/j.jaci.2014.08.008.
10
IL-4 attenuates Th1-associated chemokine expression and Th1 trafficking to inflamed tissues and limits pathogen clearance.
PLoS One. 2013 Aug 26;8(8):e71949. doi: 10.1371/journal.pone.0071949. eCollection 2013.
Zotero 插件